Fritextsökning
Artiklar per år
Innehållstyper
-
Utvecklar snabb diagnostik vid sepsis – ”Varje timme räknas”
Rätt antibiotika i rätt dos – och det med en ultrasnabb analysmetod. Gradientechs produktlösning används idag i rutindiagnostik på flera sjukhus i Europa – och nästa mål är USA-marknaden.
-
Björn Arvidsson will lead research and innovation in Region Uppsala
The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.
-
Astra Zeneca varslar i Södertälje – 70 tjänster berörs
En omorganisation på Astra Zeneca gör att runt 70 anställda i Södertälje varslas om uppsägning.
-
AI detects tumor disease – via voice recording
A short voice recording along with facial images – both analyzed with an AI algorithm – can make it possible to detect the rare tumour disease acromegaly and initiate treatment at an early stage.
-
FDA approves first non-opioid pain reliever in over 20 years
For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.
-
Government apoints new experts to medicine and health council
Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Council for Medicine and Health.
-
Marie Gårdmark: “What to expect from Trump’s second term?”
One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states political agendas, writes Marie Gårdmark in a column.
-
Life science trends 2025 – Neurology
New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-brain barrier are being developed. In addition, a new type of drug for MS is making its debut. This part of trend insights on life science 2025 is about neurology.
-
Trender inom life science 2025 – Del 4 neuro
Nya alzheimerläkemedel börjar användas, ett nytt MS-läkemedel gör entré och verktyg för att ta aktiva substanser genom blod-hjärnbarriären utvecklas. Dessutom väntas ett viktigt neurologibesked från FDA redan i dag, torsdag. Del fyra i trendspaningar 2025: neuro.
-
We desire talent to come here, but are we genuinely welcoming them?
Sweden faces significant challenges in creating a truly inclusive environment that makes international professionals feel welcome, valued, and able to build meaningful careers, writes Sarah Lidé in a column.
-
She is CSL Behring's new Nordic General Manager
Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.
-
Kinesisk investerare miljonsatsar på svenska Oncozenge
Kinesiska Sichuan Yangtian Bio-Pharmaceutical ingår ett investeringsavtal med svenska Oncozenge värt 31 miljoner kronor. Förhoppningen är att slutligen ta läkemedelskandidat Bupizenge genom fas III-studier.
-
The business coach: “We need to learn from our mistakes”
The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs can navigate these tough times, Life Science Sweden spoke to Pia Keyser, a business coach at Umeå Biotech Incubator, who has worked with many companies in the industry.
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
TLV vänder – subventionerar Roches läkemedel mot spinal muskelatrofi
TLV har beslutat att Evrysdi, ett läkemedel mot för behandling av spinal muskelatrofi, ska ingå i högkostnadsskyddet. Detta efter att tidigare bedömt att kostnaderna var för höga.
-
Affärscoachen: ”Vi behöver lära oss av våra misstag”
Det senaste året har varit tufft för många biotechbolag med flera företag som gått omkull. Hur kan konkurs undvikas? Pia Keyser, affärscoach på Umeå Biotech Incubator, har arbetat med många företag i branschen. Hon menar att entreprenörer kan identifiera och förebygga framtida problem om de tänker till i ett tidigt skede.
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according to a large American study where the connections between GLP-1 receptor agonists and the risk of a variety of health outcomes have been examined.
-
The US is leaving the WHO
The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Mellander, Director General for Trade, in an interview.
-
Life science trends 2025 – The economy
Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. Today´s part of the series with trend insights in life science for 2025 is about the economy.
-
GSK acquires oncology research company
GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.
-
The future of healthcare in focus: ”Together, things happen”
In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowledge in Sweden and around the world, according to the initiator Penilla Gunther
-
Moderna develops mRNA vaccine against norovirus
A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called “food poisoning” or the “stomach bug”.
-
Tio life science-projekt får miljonanslag – ny utlysning öppnar
En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.
BREAKING